Terms: = Skin cancer AND B2M, P61769, 567, ENSG00000166710 AND Treatment
33 results:
1. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
2. Epigenetic control of
Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
[TBL] [Abstract] [Full Text] [Related]
3. Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto P; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
Target Oncol; 2021 Nov; 16(6):789-799. PubMed ID: 34755244
[TBL] [Abstract] [Full Text] [Related]
4. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
Patel AB; Farooq S; Welborn M; Amaria RN; Chon SY; Diab A; Glitza Oliva IC; Huen AO; Li SQ; Nelson KC; Pacha O; Patel SP; Rapini RP; Tawbi HA; Wong MK; McQuade J; Davies MA; Haydu LE
Cancer; 2022 Mar; 128(5):975-983. PubMed ID: 34724197
[TBL] [Abstract] [Full Text] [Related]
5. treatment Contraindications Based on Comorbidity Status in Patients With Melanoma in the United States.
Boczar D; Bagaria SP; Spaulding AC; Huayllani MT; Avila FR; Guliyeva G; Lu X; Rinker BD; Forte AJ
Anticancer Res; 2021 Apr; 41(4):2067-2070. PubMed ID: 33813415
[TBL] [Abstract] [Full Text] [Related]
6. Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry.
Martinez-Morilla S; Villarroel-Espindola F; Wong PF; Toki MI; Aung TN; Pelekanou V; Bourke-Martin B; Schalper KA; Kluger HM; Rimm DL
Clin Cancer Res; 2021 Apr; 27(7):1987-1996. PubMed ID: 33504554
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
[TBL] [Abstract] [Full Text] [Related]
8. Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma.
Kartolo A; Holstead R; Hopman W; Baetz T
Immunotherapy; 2021 Feb; 13(3):217-225. PubMed ID: 33238773
[No Abstract] [Full Text] [Related]
9. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract] [Full Text] [Related]
10. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract] [Full Text] [Related]
11. Evaluation for skin cancer and Precancer in Patients With Vitiligo Treated With Long-term Narrowband UV-B Phototherapy.
Bae JM; Ju HJ; Lee RW; Oh SH; Shin JH; Kang HY; Park JH; Kim HJ; Jeong KH; Lee HJ; Lee S; Kim DH; Lee DY; Kim YC; Choi GS; Kim KH; Park CJ; Choi CW;
JAMA Dermatol; 2020 May; 156(5):529-537. PubMed ID: 32159729
[TBL] [Abstract] [Full Text] [Related]
12. A second expert pathology review of cutaneous melanoma in multidisciplinary meetings: Impact on treatment decisions.
Palve JS; Ylitalo LK; Luukkaala TH; Jernman JM; Korhonen NJ
Surg Oncol; 2019 Sep; 30():72-75. PubMed ID: 31500789
[TBL] [Abstract] [Full Text] [Related]
13. Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC.
Moroney LB; Ward EC; Helios J; Crombie J; Burns CL; Blake C; Comans T; Chua B; Kenny L; Hughes BGM
Support Care Cancer; 2020 Apr; 28(4):1867-1876. PubMed ID: 31352509
[TBL] [Abstract] [Full Text] [Related]
14. Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and b2m mutations in melanoma.
Richmond CS; Vallatharasu Y; Deviley JA; Vos CR; Parsons BM; Kenny PA
Exp Mol Pathol; 2019 Oct; 110():104260. PubMed ID: 31082388
[TBL] [Abstract] [Full Text] [Related]
15. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract] [Full Text] [Related]
16. Long-Term Metastatic Risk after Biopsy of Posterior Uveal Melanoma.
Bagger M; Smidt-Nielsen I; Andersen MK; Jensen PK; Heegaard S; Andersen KK; Friis S; Kiilgaard JF
Ophthalmology; 2018 Dec; 125(12):1969-1976. PubMed ID: 29705056
[TBL] [Abstract] [Full Text] [Related]
17. Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement.
Laird J; Ma J; Chau K; Chelius M; Shi W; Zhang Z; Lok BH; Yahalom J
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):670-678. PubMed ID: 29413280
[TBL] [Abstract] [Full Text] [Related]
18. Resistance to checkpoint blockade therapy through inactivation of antigen presentation.
Sade-Feldman M; Jiao YJ; Chen JH; Rooney MS; Barzily-Rokni M; Eliane JP; Bjorgaard SL; Hammond MR; Vitzthum H; Blackmon SM; Frederick DT; Hazar-Rethinam M; Nadres BA; Van Seventer EE; Shukla SA; Yizhak K; Ray JP; Rosebrock D; Livitz D; Adalsteinsson V; Getz G; Duncan LM; Li B; Corcoran RB; Lawrence DP; Stemmer-Rachamimov A; Boland GM; Landau DA; Flaherty KT; Sullivan RJ; Hacohen N
Nat Commun; 2017 Oct; 8(1):1136. PubMed ID: 29070816
[TBL] [Abstract] [Full Text] [Related]
19. Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and treatment Decisions.
Nishino M; Giobbie-Hurder A; Manos MP; Bailey N; Buchbinder EI; Ott PA; Ramaiya NH; Hodi FS
Clin Cancer Res; 2017 Aug; 23(16):4671-4679. PubMed ID: 28592629
[No Abstract] [Full Text] [Related]
20. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
[TBL] [Abstract] [Full Text] [Related]
[Next]
